X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3733) 3733
Book Review (774) 774
Publication (501) 501
Book Chapter (93) 93
Conference Proceeding (58) 58
Dissertation (28) 28
Government Document (8) 8
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2630) 2630
humans (1831) 1831
parp (1684) 1684
animals (1170) 1170
poly polymerase (1147) 1147
oncology (1019) 1019
apoptosis (932) 932
cancer (815) 815
poly polymerases - metabolism (809) 809
parp inhibitors (746) 746
biochemistry & molecular biology (737) 737
female (649) 649
parp inhibitor (617) 617
cell biology (610) 610
dna repair (600) 600
dna damage (557) 557
poly polymerase inhibitors (543) 543
mice (514) 514
cell line, tumor (463) 463
male (422) 422
homologous recombination (414) 414
breast cancer (402) 402
ovarian cancer (400) 400
chemotherapy (389) 389
pharmacology & pharmacy (380) 380
proteins (367) 367
mutation (349) 349
poly polymerase-1 (347) 347
apoptosis - drug effects (337) 337
tumors (321) 321
article (317) 317
expression (314) 314
activation (311) 311
monosaccharides (304) 304
sugars (304) 304
dna-damage (301) 301
enzyme inhibitors - pharmacology (287) 287
cells (284) 284
analysis (279) 279
repair (276) 276
deoxyribonucleic acid--dna (273) 273
olaparib (269) 269
antineoplastic agents - pharmacology (267) 267
oxidative stress (265) 265
poly polymerases - genetics (252) 252
rats (243) 243
poly (242) 242
brca1 (240) 240
dna (240) 240
research (240) 240
inhibition (239) 239
ribose (214) 214
synthetic lethality (211) 211
polymerase (206) 206
care and treatment (203) 203
genetic aspects (202) 202
gene expression (199) 199
inhibitors (196) 196
enzymes (195) 195
poly polymerase inhibitors - pharmacology (193) 193
dna-repair (191) 191
caspases - metabolism (182) 182
cell line (182) 182
cell death (180) 180
cell-death (179) 179
antineoplastic agents - therapeutic use (177) 177
cell survival - drug effects (177) 177
chemistry, medicinal (177) 177
cell cycle (175) 175
health aspects (175) 175
in-vitro (174) 174
review (170) 170
middle aged (169) 169
protein (169) 169
death (166) 166
breast-cancer (161) 161
neoplasms - drug therapy (160) 160
biophysics (159) 159
ovarian neoplasms - drug therapy (158) 158
aged (157) 157
brca2 (156) 156
neurosciences (156) 156
therapy (156) 156
adp-ribosylation (155) 155
dose-response relationship, drug (152) 152
parp inhibition (151) 151
blotting, western (150) 150
genetics & heredity (150) 150
cytotoxicity (148) 148
parp-1 (146) 146
signal transduction (146) 146
toxicology (146) 146
biology (144) 144
caspase (144) 144
adp (140) 140
brca1 protein - genetics (139) 139
cell proliferation - drug effects (139) 139
resistance (139) 139
phosphorylation (138) 138
medicine & public health (136) 136
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3753) 3753
French (32) 32
Chinese (17) 17
Japanese (15) 15
Korean (13) 13
Polish (7) 7
Czech (6) 6
German (5) 5
Russian (2) 2
Hungarian (1) 1
Persian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 11, pp. e0207399 - e0207399
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the... 
HOMOLOGOUS RECOMBINATION REPAIR | PEGYLATED LIPOSOMAL DOXORUBICIN | MULTIDISCIPLINARY SCIENCES | 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP | CERVICAL-CANCER | OPEN-LABEL | ANTITUMOR-ACTIVITY | CELL-LINES | RIBONUCLEOTIDE REDUCTASE-ACTIVITY | ENDOTHELIAL GROWTH-FACTOR | TUMOR-CELL | Humans | Mice, SCID | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | BRCA1 Protein - metabolism | Cell Line, Tumor | Female | Pyridines - pharmacology | Thiosemicarbazones - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | BRCA mutations | Patient outcomes | Development and progression | Genetic aspects | Drug therapy, Combination | Drug therapy | Health aspects | Methods | Ovarian cancer | Animal models | Severe combined immunodeficiency | Ovarian carcinoma | Xenotransplantation | Homologous recombination | Homology | AKT protein | Kinases | Homologous recombination repair | Ribonucleotide reductase | Xenografts | Protein-tyrosine kinase receptors | Vascular endothelial growth factor | Growth factors | Protein-tyrosine kinase | Tyrosine | Effectiveness | Poly(ADP-ribose) polymerase | Breast cancer | Survival | Inhibitors | Cell lines | Mice | Mutation | Prolongation | Cancer | Tumors | Apoptosis | Reductase | Index Medicus
Journal Article
Journal of Veterinary Medical Science, ISSN 0916-7250, 2018
Cerebral ischemia is a neurological disorder with high mortality. Quercetin is a flavonoid compound that is abundant in vegetables and fruits. It exerts... 
neuroprotection | quercetin | PARP | caspase-3
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/2012, Volume 166, Issue 2, pp. 617 - 636
GaQ | ROS | PARP | Ca | p53
Journal Article
Microbes and Infection, ISSN 1286-4579, 2019
Protein ADP-ribosylation is a reversible post-translational modification, which alters protein activity, localization, interactome or stability, leading to... 
Infection | Bacteria | PARP | Immunity | ADP-ribosylation | ARTD
Journal Article
CELLS, ISSN 2073-4409, 02/2019, Volume 8, Issue 2, p. 137
Increased DNA damage and the propension to cancer development, depend on the modulation of the mechanisms to control and maintain genomic integrity.... 
automodified PARP (PAR-PARP) | greenhouses | PARPS | Poly(ADP-Ribose)Polymerase | pesticides | DNA damage | growers | CELL BIOLOGY
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 10/2016, Volume 30, Issue 4, pp. 637 - 650
Poly (ADP-ribose) polymerase inhibitors (PARPis) are clinically effective predominantly for BRCA-mutant tumors. We introduce a mechanism-based strategy to... 
AML | DNMT inhibitor | DNMT1 | PARP trapping | DNA damage | PARP inhibitor | breast cancer | PARP | DNA double-strand break | DNA repair | POLY(ADP-RIBOSE) POLYMERASE | DECITABINE | METHYLATION | BASE EXCISION-REPAIR | LETHALITY | ONCOLOGY | DOUBLE-STRAND BREAKS | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | MAMMALIAN-CELLS | ADP-RIBOSE POLYMERS | CELL BIOLOGY | Chromatin - metabolism | Humans | Leukemia, Myeloid, Acute - metabolism | Male | Poly (ADP-Ribose) Polymerase-1 - metabolism | Triple Negative Breast Neoplasms - drug therapy | DNA Breaks, Double-Stranded | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Animals | Triple Negative Breast Neoplasms - genetics | Mice, Nude | Triple Negative Breast Neoplasms - metabolism | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Female | Mice, Inbred NOD | Mice | DNA Methylation - drug effects | Leukemia, Myeloid, Acute - genetics | Medical colleges | Care and treatment | Chromatin | Leukemia | Epidemiology | Monosaccharides | Gerontology | Methyltransferases | Analysis | DNA | Genetic aspects | Health aspects | Sugars | Cancer | Index Medicus
Journal Article
Future Oncology, ISSN 1479-6694, 02/2017, Volume 13, Issue 4, pp. 307 - 320
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 6/2017, Volume 23, Issue 12, pp. 3097 - 3108
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 09/2019, Volume 23, Issue 9, pp. 773 - 785
Introduction: The implementation of poly-ADP-ribose polymerase (PARP) inhibitors for therapy has created potential treatments for a wide spectrum of... 
prostate cancer | DNA damage response | BRCA mutations | ovarian cancer | PARP inhibitors | breast cancer | BRCAness | PARP enzymes | Index Medicus
Journal Article
Cell Cycle, ISSN 1538-4101, 08/2019, Volume 18, Issue 15, pp. 1770 - 1783
Although improvements in radiation therapy were made over the years, radioresistance is still a major challenge. Cancer cells are often deficient for DNA... 
proton radiation | PARP | RAD51 | delayed cell death | cell cycle arrest | synthetic lethality | LUNG | APOPTOSIS | INCREASES | INDUCED SENESCENCE | CANCER | CELL BIOLOGY | THERAPY | RADIOSENSITIZATION | CISPLATIN | PARP INHIBITION | HOMOLOGOUS RECOMBINATION
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2010, Volume 16, Issue 18, pp. 4532 - 4542
Tumor cells are often deficient in DNA repair and damage response (DDR) pathways, and anticancer therapies are commonly based on genotoxic treatments using... 
indenoisoquinolines | PARP | poly(ADP-ribose) | DNA repair | γH2AX | pharmacodynamics
Journal Article
Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, 09/2019, Volume 37, Issue 14, pp. 3637 - 3648
The Wnt/β-catenin pathway plays an important regulatory role in cancer signaling and cell regenerative mechanisms. Its suppression has long been considered as... 
PARP | colorectal cancer | virtual screening | molecular dynamics | tankyrase | BIOPHYSICS | MECHANISM | DATABASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | PARP INHIBITORS | BINDING
Journal Article
GYNECOLOGIC ONCOLOGY, ISSN 0090-8258, 05/2019, Volume 153, Issue 2, pp. 416 - 424
Purpose. PARP inhibitor maintenance therapy in platinum sensitive sporadic ovarian cancers improves progression free survival. However, biomarker for synthetic... 
LUNG | Biomarker | Synthetic lethality | DNA repair | MAINTENANCE THERAPY | Ovarian cancer | OBSTETRICS & GYNECOLOGY | CISPLATIN | ONCOLOGY | ERCC1 | Predictive | XPF: PARP | PARP INHIBITORS | EXPRESSION | Index Medicus
Journal Article
CANCER SCIENCE, ISSN 1349-7006, 01/2018, Volume 109, pp. 559 - 559
Conference Proceeding
Neuropharmacology, 09/2019, pp. 107755 - 107755
Poly(ADP-ribose) polymerase-1 (PARP1) is a ubiquitous nuclear enzyme that regulates DNA repair and genomic stability. In oxidative genotoxic conditions, PARP1... 
Index Medicus
Journal Article
The Journal of Pathology, ISSN 0022-3417, 02/2013, Volume 229, Issue 3, pp. 422 - 429
Journal Article
by Lu, HY and Bai, L and Zhou, YP and Lu, YP and Jiang, ZL and Shi, JY
CURRENT TOPICS IN MEDICINAL CHEMISTRY, ISSN 1568-0266, 2019, Volume 19, Issue 12, pp. 1041 - 1050
The occurrence and development of tumors are closely related to epigenetic instability which modulates gene expression through DNA methylation, histone... 
HDAC INHIBITORS | CANCER-CELLS | APOPTOSIS | HISTONE DEACETYLASE INHIBITOR | CHEMISTRY, MEDICINAL | STRAND-BREAK REPAIR | PARP | COMBINATION | PARP INHIBITOR | Dual inhibitors | Epigenetics | Tumor | Synergy | DNA-REPAIR | PHASE-I | DERIVATIVES | HDAC
Journal Article
DNA Repair, ISSN 1568-7864, 10/2019, Volume 82, pp. 102697 - 102697
Homologous recombination deficiency conferred by alterations in or are common in breast tumors and can drive sensitivity to platinum chemotherapy and PARP... 
Nucleotide excision repair | Breast cancer | Cisplatin | PARP inhibitor | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.